Oncimmune Holdings plc announced the appointment of Professor Tariq Sethi as Chief Scientific Officer, Matthew Luttrell as Chief Commercial Officer and Cléa Rosenfeld as Head of Investor Relations. Prior to joining Oncimmune, Tariq was Chief Physician Scientist, Vice President in the Clinical Discovery Unit AstraZeneca and Emeritus Professor of Respiratory Medicine King's College London. Tariq joins in the company as from 1 October 2019 as its Chief Scientific Officer, and will also become part of the Senior Leadership Team. Prior to joining in the company as Chief Commercial Officer, Matthew was Head of Haematology, Growth and Emerging Markets at Shire (now Takeda). Matthew also joins the Senior Leadership Team at the company as from 1 October 2019. Cléa Rosenfeld joined the Oncimmune team as Head of Investor Relations in July 2019.